OCUMETICS Aktie

 

Calgary, Alberta – TheNewswire - June 26, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the successful completion of a virtual site initiation visit at its clinical partner site in Mexico City. This critical milestone confirms that the investigative site is fully prepared to conduct the upcoming first-in-human (FIH) clinical study of its revolutionary accommodating intraocular lens (the “Ocumetics Lens”), in accordance with international standards. Dean Burns, CEO of Ocumetics commented on the significance of the site inspection: “Conducting the clinical partner site initiation is a major step forward in bringing the Ocumetics Lens to clinical reality. The site initiation occurred remotely and will be finalized when our team visits the site. Successful completion of this critical process confirms clinical readiness to commence the study and to perform surgeries on ...

  Calgary, Alberta – TheNewswire - June 24, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to confirm the culmination of nearly two decades of research and development as it prepares for first-in-human (FIH) clinical studies of its revolutionary accommodating intraocular lens (the “Ocumetics Lens”). “This moment is nothing short of transformational,” said Dean Burns, CEO of Ocumetics.  “With clinical study site initiation set to begin this week, we are now taking the most significant step yet in bringing the Ocumetics Lens to market.  What began as a dream to restore the youthful eye's natural ability to focus distant and near objects after cataract surgery is one step closer to becoming a reality.  With a world class team, innovative technology, and unwavering determination, we are redefining what's possible in ophthalmology.” This summer marks a groundbreaking lea...

    Calgary, Alberta – TheNewswire - June 4, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “Offering”) of up to 6,000,000 units of the Corporation (“Units”) at a price of $0.35 per Unit for gross proceeds of up to $2,100,000. There will be no minimum subscription level for the Offering.  Each Unit will consist of one common share in the share capital of the Corporation (“Common Share”) and one-half of one common share purchase warrant. Each whole warrant (“Warrant”) will entitle the holder to purchase one additional Common Share at an exercise price of $0.50 for a period of 24 months from the date of issuance of the Warrant.   The Warrants will be subject to an acceleration clause such that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at ‎‎least $0.60 per Common Share for a period of 30 consecutiv...

    Calgary, Alberta - TheNewswire - – June 3, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has set June 26, 2025 as the date for its first-in-human (FIH) clinical study.   The FIH clinical study involves the implantation of the Company's inaugural accommodating intraocular lens (the “Ocumetics Lens”) in the first group of study patients at a designated clinic in Mexico City.  This milestone marks a historic moment for Ocumetics - culminating nearly two decades of relentless innovation, research, and development.   Dean Burns, CEO of Ocumetics, expressed the Company's excitement, “June 26, 2025 will be a landmark day not just for Ocumetics, but for the entire field of ophthalmology. The implantation of our accommodating intraocular lenses in the first group of patients is the culmination of over 18 years of vision, planning, engineering, and perseve...

    Calgary, Alberta – TheNewswire - June 2, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that the first-in-human (FIH) clinical study for its revolutionary accommodating intraocular lens (the “Ocumetics Lens”) will take place in Mexico City.  This follows a strategic decision to relocate the study from its originally planned site in the Dominican Republic that will allow Ocumetics to take advantage of resources that better meet the Company's needs.   Dean Burns, CEO of Ocumetics commented, “The Ocumetics team demonstrated outstanding agility and professionalism in managing the site relocation.  After a detailed analysis of alternative sites and their resources, we chose a site in Mexico City because it meets all protocol requirements and offers a strong foundation for clinical studies.  Mexico City provides an ideal environment for this pivotal study with ...

Calgary, Alberta – TheNewswire - May 22, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the submission of its first-in-human (FIH) clinical study protocol for IRB approval.  This development represents a critical step in the advancement of the Ocumetics Lens toward clinical trials planned for summer 2025, designed to assess safety, effectiveness, and performance of Ocumetics' innovative lens technology in human subjects for the first time. Dean Burns, CEO of Ocumetics, stated: “The development of our first-in-human study protocol is a major step forward and reflects our commitment to scientific rigor and patient safety.  With the protocol and study endpoints now in place, we are preparing for regulatory submission and study site initiation.  We are excited to move into the clinical phase of development with strong partners and a clear path forward.” The FIH study...

  Calgary, Alberta – TheNewswire - May 14, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce it has successfully manufactured its inaugural accommodating intraocular lenses (the “Ocumetics Lens”) for use in its upcoming first-in-human (FIH) clinical study planned for summer 2025. Each Ocumetics Lens produced has demonstrated, using the IOLA lens analyzer, consistent quality and precision in alignment with study requirements and stringent clinical standards.   Dean Burns, President and CEO of Ocumetics, stated: “Our international design teams have worked diligently to refine and validate our production protocols. I'm confident that the manufacturing processes developed by our team will deliver the consistency in lens quality that is not only essential for clinical trial success but also vital to Ocumetics' long-term vision of commercial scalability. This is a proud m...

Calgary, Alberta – TheNewswire - May 12 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the successful completion of its optimized lens prototype design. With this milestone, Ocumetics has formally initiated a design freeze - locking in lens specifications that will be used in its upcoming first-in-human (FIH) clinical study planned for summer 2025. Dean Burns, CEO of Ocumetics, stated: “This is a defining milestone for Ocumetics.  This optimized lens design reflects our commitment to precision, performance, and patient safety. With the design now locked, we can advance with the manufacturing and regulatory processes leading up to our first-in-human studies planned for this summer. With each completed step the path to delivering a transformative solution for vision correction is clearer than ever.” This decision follows a series of rigorous design optimizations, bench...

Calgary, Alberta – TheNewswire - May 8, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce a significant breakthrough in its development of next-generation intraocular lens technology. In recent laboratory testing, the Company successfully demonstrated accommodative power change using 3D-printed moulded lenses under simulated ciliary body compression conditions - marking a pivotal step forward in the pursuit of restoring youthful vision.  Accommodative power refers to the eye's ability to focus between near and far distances following lens replacement surgery.   Dean Burns, CEO of Ocumetics, stated: “These results represent a critical milestone for Ocumetics and for the future of ophthalmology. The data supports our confidence in the platform and strengthens our commitment to delivering a lens that not only corrects vision but restores the natural focusing ability lost wi...

    Calgary, Alberta – TheNewswire - May 1, 2025 - Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) (the “Corporation” or “Ocumetics”) announces that Mr. Dayton Marks has resigned as a director of the Corporation.   “On behalf of the Ocumetics board of directors, I would like to thank Dayton for his contributions to Ocumetics,” said Dr. Garth Webb, Ocumetics' Founder and Chairman of the Board. “We are thankful for his significant efforts and contributions to the Corporation. We wish him well in his future endeavours.”   About Ocumetics   Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.   Ocumetics is...

Calgary, Alberta – TheNewswire - April 22, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the achievement of several key milestones paving the way for its First-In-Human (“FIH”) clinical study of the Company's innovative accommodating intraocular lens (the “Ocumetics Lens”). “Advancing a medical device like the Ocumetics Lens from concept to First-In-Human evaluation requires a rigorous, structured process to ensure safety, efficacy, and full regulatory compliance,” said Dean Burns, President and CEO of Ocumetics. “With the recent completion of numerous critical advancements, we're excited to share our roadmap toward FIH clinical trials, which are set to begin in the coming months,” adds Burns. “The FIH surgery and Initial study results are expected this summer, with full results anticipated in the fall. We also expect to submit an application to the FD...

Calgary, Alberta – TheNewswire - March 24, 2025 – Ocumetics Technology Corp. (“Ocumetics”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that, subject to regulatory approval, it has engaged the services of Independent Trading Group ("ITG") to provide market-making services in accordance with TSX Venture Exchange “TSXV” policies. ITG will trade shares of Ocumetics on the TSXV and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of Ocumetics' common shares. Under the agreement, ITG will receive compensation of CA$7,000 per month, payable monthly in advance. The agreement is for an initial term of one month and will renew for additional one-month terms unless terminated. The agreement may be terminated by either party with 30 days' notice. There are no performance factors contained in the agreement and ITG will not receive shares or options as compensation. ITG and Oc...

Calgary, Alberta – TheNewswire - March 11, 2025.  Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has appointed Michael Edwards, BBA, CPA, CA, CLU, to its Board of Directors.   “We are thrilled to have Michael join our board of directors,” says Dr. Garth Webb, founder and Chairman of Ocumetics. “Michael has an extensive background in accounting, taxation, corporate governance and fundraising in Canada,” adds Dr. Webb. “This experience will be invaluable as we navigate the next phase of our growth.” Michael graduated from Acadia University with a Bachelor of Business Administration and thereafter obtained his C.A. designation, achieving the highest provincial standing (PEI) on the Uniform Final Exams. Michael spent several years working for public accounting firms in increasing areas of responsibility, and completed the CICA In-Depth Tax Course.   Micha...

  Calgary, Alberta – TheNewswire - January 24, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, announces that it has issued an aggregate of 5,000,000 restricted share units (each, a “Unit”) to Grit Marketing Inc. under the Corporation's restricted share unit plan (the “RSU Plan”).  Grit Marketing Inc. (the “Consultant”) is the consulting company of Dean Burns, the President and Chief Executive Officer of the Corporation. The Units shall vest in installments upon the achievement of certain performance milestones, up to a maximum of 5,000,000 Units, provided that in no event shall any Unit vest until one year after the date of grant.  All non-vested Units shall expire on January 23, 2030, subject to earlier termination if the Consultant ceases to be an eligible participant under the RSU Plan.  Each vested Unit shall entitle the Consultant to receive one Common Share in the sha...

    Calgary, Alberta – TheNewswire - November 22, 2024 - Ocumetics Technology Corp. (“Ocumetics”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to provide an update on internal test results of its recently manufactured accommodative intraocular lenses (“AIOL”).   During internal testing of lenses manufactured for its upcoming first in human (“FIH”) trials, the design team identified an opportunity to improve the lens design to further enhance its performance and safety profile.   “During internal lab testing, we identified an opportunity to make important improvements to our AIOL design, without incurring significant costs or delays,” says Dean Burns, President and CEO of Ocumetics. “Our commitment to excellence in ophthalmic technology dictates that we incorporate these design enhancements into the lens prior to FIH studies,” adds Burns.   To manufacture the optimized lenses, Ocumetics must re-order raw materials, create new l...

  Calgary, Alberta – TheNewswire - August 29, 2024 - Ocumetics Technology Corp. (“Ocumetics”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a pioneer in vision enhancement technology, is pleased to announce the successful fabrication of an intraocular lens (IOL) that is designed to respond to muscle activity that controls the curvature of the natural lens in the human eye.  This achievement puts Ocumetics one step closer to the first human implantation scheduled to occur in early 2025.   Accommodation is the ability to change the focus of the eye from distance to near.  Accommodation is based on the ability of the natural lens of the eye to change its shape in response to forces exerted by the ciliary muscles, which surround the natural lens of the eye.   The Ocumetics accommodating IOL is designed to respond to these same natural forces by changing its shape in a way that changes its curvature and ultimately, its focus from near objects to objects in the distance.  Using a precise measuring device ...

    Calgary, Alberta – TheNewswire - August 8, 2024 - Ocumetics Technology Corp. (“Ocumetics”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a pioneer in vision enhancement technology, is excited to announce the successful development of a new injector system specifically designed for implantation of the Ocumetics Accommodative Intraocular lens (the “Ocumetics Lens”).  This achievement marks a significant milestone in Ocumetics' journey toward its first-in-human study scheduled for early 2025.   The new injector, meticulously crafted by Medicil, a renowned Swiss IOL (intraocular lens) injector manufacturer, is tailored to the unique specifications of the Ocumetics Lens, ensuring precise and efficient implantation.  This development is crucial for optimizing the surgical procedure, performance, and patient outcomes of this innovative lens, which is designed to provide optimal visual performance at all distances and improved quality of life for individuals with visually significant cataracts.   ?...

  Calgary, Alberta – TheNewswire - July 22, 2024 - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in vision enhancement technology, is pleased to announce that its intraocular lenses are now being manufactured for the upcoming first-in-human study in the Dominican Republic. “We are thrilled to collaborate with Bioana, leveraging their medical device expertise and cutting-edge manufacturing facilities to bring our innovative intraocular lenses to life,” said Dean Burns, CEO of Ocumetics Technology Corp.  “Producing these lenses is a critical milestone in our mission to provide clear distance and near vision after cataract surgery.” The Ocumetics lenses promise groundbreaking enhancements to vision correction technology. Designed to provide excellent visual acuity at all distances and improved quality of life for patients, these lenses are set to be evaluated in an upcoming first-in-human clinical study in the Dominican Repu...

  Calgary, Alberta – June 24, 2024. - TheNewswire - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the second tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024 and May 23, 2024. The Corporation has issued secured convertible debentures having an aggregate face value principal amount of $1,000,000 (the “Principal”).  The debentures were subject to an original issue discount of 6%, resulting in net proceeds to the Corporation of $940,000 (the “Net Proceeds”), less expenses incurred by the lenders in respect of the offering.   The debentures bear interest at rate of 18% per annum, compounded annually.  The Debentures will mature, and Principal and interest will be payable by the Corporation, on the date which is two years from the date of issue.  The Corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior...

Calgary, Alberta – June 21, 2024. - TheNewswire - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the second tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024 and May 23, 2024. The Corporation has issued secured convertible debentures having an aggregate face value principal amount of $1,000,000 (the “Principal”).  The debentures were subject to an original issue discount of 6%, resulting in net proceeds to the Corporation of $940,000 (the “Net Proceeds”), less expenses incurred by the lenders in respect of the offering.   The debentures bear interest at rate of 18% per annum, compounded annually.  The Debentures will mature, and Principal and interest will be payable by the Corporation, on the date which is two years from the date of issue.  The Corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior wr...